Monroe Capital (MRCC) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
11 Mar, 2026Executive summary
Supplement updates the joint proxy statement/prospectus for the proposed asset sale and merger between two entities, reflecting recent developments and shareholder engagement since January 2026.
Following a reduction in quarterly distributions and a drop in trading prices, both companies engaged with shareholders to address concerns and maintain support for the merger.
New proposals include a $13 million supplemental distribution to MRCC shareholders and additional distributions to the combined company's shareholders for two quarters post-merger.
Both boards and special committees reviewed and supported these enhancements, considering market conditions and the impact on the combined entity's net asset value.
Forward-looking statements highlight risks, uncertainties, and anticipated benefits, including improved operations, enhanced revenues, and growth potential for the combined company.
Voting matters and shareholder proposals
Shareholders are being solicited to vote on the asset sale and merger proposals, with supplemental distributions contingent on approval.
Proxy solicitation involved extensive engagement with shareholders to ensure support for the proposals.
Board of directors and corporate governance
Special committees of both boards met to evaluate the impact of supplemental distributions and to ensure fiduciary duties were met.
Independent directors and legal advisors participated in deliberations regarding the structure and fairness of the proposals.
Latest events from Monroe Capital
- Both asset sale and merger proposals were approved by a majority of outstanding shares.MRCC
EGM 202613 Mar 2026 - Supplement updates proxy materials for a proposed transaction, referencing recent filings.MRCC
Proxy Filing6 Mar 2026 - Net investment income and NAV declined year-over-year, with merger expected to unlock value.MRCC
Q4 20255 Mar 2026 - Director election and share sale authorization approved; no shareholder questions raised.MRCC
AGM 20243 Feb 2026 - Adjusted NII rose to $0.31/share, covering the dividend as NAV and leverage declined.MRCC
Q2 20242 Feb 2026 - Shareholders to vote on merger and asset sale, with NAV-based share exchange and fee waiver.MRCC
Proxy Filing20 Jan 2026 - Dividend coverage strong, NAV dipped, non-accruals up, Wendel partnership adds $1B capital.MRCC
Q3 202414 Jan 2026 - Q4 income covered dividends; NAV dipped, but 2025 outlook targets growth and risk discipline.MRCC
Q4 202416 Dec 2025 - Shareholders to vote on unchanged advisory agreement after Wendel acquires 75% of Monroe.MRCC
Proxy Filing2 Dec 2025